英伯克斯生物科技 INBX

Mr. Lappe has served as our Chief Executive Officer and as a member of our Board of Directors since January 2024 and prior to that, co-founded the Former Parent in 2010 and served as its Chief Executive Officer and chairman of the board of directors from its inception to May 2024. Mr. Lappe has extensive expertise in the biotechnology industry with over thirty years of experience in executive management, investment management and executive recruiting, having built the executive teams of over forty start-up biotechnology and medical device companies. Prior to founding Inhibrx, Mr. Lappe was the founder and Managing Partner of Efficacy Biotech Fund, a fund focused on strategic investment in public biotechnology companies.

Mr. Matly was appointed as our President in April 2025, assuming oversight of the Company's clinical development and operations, research and development, technical operations, and regulatory affairs, and adding to his roles as Chief Commercial and Business Development Officer, in which he served as an Executive Vice President since May 2024. Mr. Matly joined the Former Parent in October 2021 and has been responsible for all commercial, medical affairs, market access and business development functions at Inhibrx. He brings extensive commercial launch and business development experience across both biotechnology and large pharmaceutical companies. Previously, Mr. Matly was at Novartis, where he most recently served as the global Vice President of the MDS/AML franchise from 2020 to 2021. In this role, he was responsible for the launch preparation of their flagship program and building the MDS/AML portfolio, including the evaluation of in-licensing and M&A opportunities. Prior to this role, Mr. Matly was Novartis Oncology's global commercial lead of the sickle cell disease therapeutic area from 2018 to 2020, leading the launch of ADAKVEO and also serving as the global commercial lead of PROMACTA/REVOLADE from 2017 to 2018. Prior to Novartis, Mr. Matly was the Vice President of Business Development at Chrono Therapeutics. Mr. Matly began his career at Eli Lilly, holding several positions of increasing responsibility in sales and marketing, most notably leading the US launch of CYRAMZA in metastatic lung cancer. Mr. Matly received his B.S. in Industrial Engineering from Purdue University and his M.B.A. from Harvard Business School.

Ms. Deck has served as our Chief Financial Officer since May 2024 and leads our accounting, finance, information technology, and investor relations functions. She joined the Former Parent in October 2018 as Vice President of Finance, bringing decades of experience in the life science industry, and served as the Former Parent's Chief Financial Officer from April 2020 until May 2024. Prior to joining our team, Ms. Deck held various accounting and finance positions of increasing responsibility with Apricus Biosciences, Inc., Hologic, Inc., Gen-Probe, Inc., and Cytori Therapeutics, Inc. Ms. Deck is currently the treasurer of the board of trustees for the Fleet Science Center. Ms. Deck holds a B.S. and M.S. in Accounting and is an active licensed Certified Public Accountant in the state of California.

Dr. Kayyem has served as a member of our Board since May 2024 and previously served as a member of the Former Parent's board of directors from April 2018 until May 2024. He is the founder of GenMark Diagnostics Inc. (GenMark) and from May 2010 until February 2018, Dr. Kayyem served in various leadership positions at GenMark including Senior Vice President of Research and Development, Chief Scientific Officer, President, and Chief Executive Officer as the company evolved from Osmetech plc. In 2018, Dr. Kayyem became a consultant to GenMark's board of directors and executive team. In March 2021, GenMark agreed to merge with Roche, which subsequently acquired GenMark through a tender offer. In 2006, Dr. Kayyem founded and served as a member of the board of directors of privately-held Calimmune, Inc. until its acquisition by CSL Behring in 2017. In 1995, he founded Clinical Micro Sensors, Inc. to commercialize technical innovations he developed while serving as a Senior Research Fellow at the California Institute of Technology (Caltech). In 2000, Clinical Micro Sensors, Inc. was sold to Motorola, Inc. and was subsequently purchased by Osmetech plc in 2005. From June 2000 until December 2004, Dr. Kayyem served as Vice President of Life Sciences at Motorola. In October 2004, he co-founded the biotechnology fund management company, Efficacy Capital Limited, and, until September 2009, served as a managing partner. Dr. Kayyem currently serves as a member of the board of directors of Biodesix, Inc., a public company, and Bexorg, Inc., a non-public company. He also currently serves, or has served, as a director or advisor on various other non-public company boards, including non-profit and educational institutions. Dr. Kayyem received a combined B.S. and M.S. in Molecular Biophysics and Biochemistry from Yale University and a Ph.D. in Molecular Biology from Caltech.

Ms. Manhard has served as a member of our Board since May 2024 and previously served as a member of the Former Parent's board of directors from June 2020 until May 2024. Ms. Manhard has served as the Chief Development Officer, Executive Vice President for Connect Biopharma Holdings Limited (Connect Biopharma) since September 2024. Prior to Connect Biopharma, Ms. Manhard served as the Senior Vice President of Global Strategic Planning and Execution for Acadia Pharmaceuticals Inc. from January 2024 to September 2024, and as the Executive Vice President, Drug Development of Heron Therapeutics, Inc. (Heron) from January 2016 to June 2023. She also served as a director of Heron from 2014 to 2016 and from 2019 to February 2023. From 2006 to 2016, she served as the Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences, Inc. (Ardea). In her role at Ardea, Ms. Manhard was instrumental in the development and 2015 regulatory approval of lesinurad (Zurampic). Prior to joining Ardea in 2006, she was President of her own consultancy firm, Vice President of Regulatory Affairs for Exelixis, Inc., and held multiple regulatory positions at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, supporting development and commercialization of anticancer and antiviral products, including nelfinavir (Viracept). Ms. Manhard was also previously with Bristol-Myers Squibb Company in regulatory affairs, responsible for oncology compounds, including paclitaxel (Taxol) and infectious disease compounds, including didanosine (Videx) and stavudine (Zerit). Ms. Manhard began her career in clinical research with Eli Lilly and Company and G.H. Besselaar Associates (Covance Inc.). Ms. Manhard currently serves as a member of the board of directors of Toragen, Inc. and previously served as a member of the board of directors of Shoreline Biosciences Inc. She received a B.S. degree in zoology and a B.A. degree in French from the University of Florida.